Welcome to our dedicated page for Certara news (Ticker: CERT), a resource for investors and traders seeking the latest updates and insights on Certara stock.
Certara, Inc. (NASDAQ: CERT) delivers biosimulation solutions and model-informed drug development services that accelerate pharmaceutical innovation. This page provides comprehensive coverage of Certara's latest news, including regulatory milestones, strategic partnerships, and advancements in simulation technology.
Investors and industry professionals will find timely updates on earnings reports, product launches, and scientific developments shaping the drug development landscape. Our curated collection features press releases on regulatory submissions, technology platform enhancements, and collaborations with biopharma leaders.
Key focus areas include Certara's biosimulation software updates, regulatory science achievements, and innovations in quantitative pharmacology. Bookmark this page to stay informed about developments impacting clinical trial optimization and global drug approval processes.
Certara reported Q1 fiscal 2021 results with revenue of $66.7 million, a 16% increase from Q1 2020. Net income rose to $1.1 million, with adjusted EBITDA climbing 20% to $23.9 million. The company updated its full-year guidance, projecting revenue between $277 million and $285 million, and adjusted EBITDA of $100 million to $102 million. First quarter bookings grew 34% year-over-year, indicating strong demand for its biosimulation platform.
Certara has launched its innovative Secondary Intelligence™ software, designed to predict off-target safety issues that could affect drug development. This software is the first of its kind, providing critical data on secondary pharmacology and enhancing decision-making for drug developers. With safety issues contributing to around 25% of candidate failures, this tool aims to improve the efficiency and precision of safety assessments, potentially accelerating clinical success. Certara serves over 1,650 clients in 61 countries, highlighting its significant role in the biopharmaceutical sector.
Certara, Inc. (Nasdaq: CERT), a leader in biosimulation, announced its participation in the BofA Securities 2021 Virtual Health Care Conference. The presentation will be led by CEO William Feehery and CFO Andrew Schemick on May 11, 2021, at 2:45 p.m. ET. A live webcast will be available on Certara’s investor relations website, with a replay option for 90 days. Certara specializes in accelerating drug discovery and development through innovative biosimulation technology, serving over 1,650 clients globally, including major biopharmaceutical firms and regulatory agencies.
Certara, Inc. (Nasdaq: CERT) announced it will release preliminary financial results for Q1 2021 on May 6, 2021, after market close. A conference call will follow at 5:00 p.m. ET for management to discuss these results. Investors can participate via phone or listen to the archived webcast on Certara's website. Certara specializes in biosimulation software, serving over 1,650 biopharmaceutical companies and regulatory agencies worldwide, enhancing drug discovery and development processes.
Certara announced the successful closing of its underwritten public offering of 11,500,000 shares of common stock at $25.00 per share. This includes 1,500,000 shares sold due to the full exercise of underwriters’ options. Notably, Certara and its management did not sell any shares and received no proceeds from this offering. The transaction was conducted by leading underwriters including Jefferies, Morgan Stanley, and BofA Securities. The offering was registered under the SEC with an effective registration statement on Form S-1.
Certara, Inc. (Nasdaq: CERT) has announced the pricing of its underwritten public offering of 10 million shares of common stock by existing stockholders at $25.00 per share. The underwriters have a 30-day option to purchase up to an additional 1,500,000 shares. Certara will not receive any proceeds from this offering. The closing is anticipated around March 29, 2021, subject to customary conditions. The offering is managed by Jefferies, Morgan Stanley, and BofA Securities.
Certara, Inc. announced a proposed underwritten public offering of 17 million shares of its common stock by selling stockholders, with an additional 2,550,000 shares available for purchase by underwriters. Certara will not receive proceeds from this offering. The underwriting team includes Jefferies, Morgan Stanley, and BofA Securities. A preliminary registration statement has been filed with the SEC but is not yet effective, meaning no sales can occur until it is approved. This initiative supports Certara's ongoing role in biosimulation technology for drug development.
Certara (Nasdaq: CERT) has licensed TrialAssure's ANONYMIZE software to enhance anonymization of clinical data. This collaboration allows Certara's regulatory science division, Synchrogenix, to offer tailored anonymization services as a SaaS model to over 1,650 global biopharmaceutical clients. The ANONYMIZE tool enables full configurability to sponsor specifications, leveraging machine learning for efficient data processing. This partnership aims to strengthen compliance with increasing regulatory demands for data transparency in clinical trials.
Certara, a leader in biosimulation, is set to join the Russell 1000® Index effective March 22, 2021. This inclusion is based on its strong financial performance and reflects the growing adoption of its biosimulation platform. The Russell 1000 Index tracks the 1,000 largest companies in the U.S., and membership can enhance visibility among institutional investors, with approximately $9 trillion in assets benchmarked to these indexes. Certara aims to leverage this milestone to increase stock awareness within the investment community.
Certara, a leader in biosimulation, reported its preliminary results for Q4 and the full year 2020. Q4 revenue reached $64.6 million, with a full-year total of $243.5 million, reflecting growths of 20% and 17% year-over-year, respectively. However, the company recorded a net loss of ($54.4 million) in Q4 and ($49.4 million) for the full year, an increase from previous losses. Adjusted EBITDA grew by 36% in Q4 and 28% for the year. Certara anticipates 2021 revenue between $272 million and $285 million.
